In the future, SPADE's goal is for multiple diagnostic tests to be performed on a single tissue sample, extracting more information without repeatedly putting the patient through biopsies. Researchers could also identify several drug targets from the same sample, opening up possibilities for combination therapies. Towards this goal, NCCS has signed a Research Collaboration Agreement with 10x Genomics, a biotechnology company specialising in single-cell and spatial biology, providing access to advanced spatial profiling technology and supporting new research applications.
SPADE has an even bigger ambition: to build a spatial tissue atlas — a comprehensive molecular map of human tissue. Such an atlas could provide researchers with vast amounts of data to train AI models and develop simulations of how diseases behave.
The longer-term ambition is to move medicine towards something more individualised, away from generalised treatment assumptions. SPADE is SingHealth Duke-NUS AMC's goal to look at diseases not as a single diagnosis, but as a complicated ecosystem of cells — because ultimately, understanding diseases in greater detail helps doctors make better decisions and gives patients a better chance at living well.
This article was first published on 12 November 2026.